Published in Lancet on July 12, 2003
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol (2011) 0.98
Proteomic profiling of KATP channel-deficient hypertensive heart maps risk for maladaptive cardiomyopathic outcome. Proteomics (2009) 0.91
Guideline compliance in chronic heart failure patients with multiple comorbid diseases: evaluation of an individualised multidisciplinary model of care. PLoS One (2014) 0.88
K(ATP) channel-dependent metaboproteome decoded: systems approaches to heart failure prediction, diagnosis, and therapy. Cardiovasc Res (2011) 0.86
N-Terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction. A study in patients presenting with suspected cardiac disorders. Z Kardiol (2005) 0.86
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84
Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases. Heart Fail Rev (2010) 0.80
Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age? Br J Clin Pharmacol (2006) 0.80
Inter-professional team approach to patients with heart failure. Heart (2005) 0.79
Heart failure: treatment and ethnic origin. Lancet (2003) 0.76
Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review. Curr Cardiol Rev (2016) 0.76
Oxidative stress contributes to the impaired sonic hedgehog pathway in type 1 diabetic mice with myocardial infarction. Exp Ther Med (2015) 0.75
Management Of Atrial Fibrillation In Patients With Heart Failure. J Atr Fibrillation (2014) 0.75
Heart failure: treatment and ethnic origin. Lancet (2003) 0.75
Predictors of better self-care in patients with heart failure after six months of follow-up home visits. Nurs Res Pract (2013) 0.75
Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC Heart Fail (2017) 0.75
The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension (2009) 2.47
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A (2007) 1.82
Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol (2005) 1.67
Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int (2003) 1.61
Urotensin II: a new player in vascular and myocardial disease? Clin Sci (Lond) (2003) 1.59
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol (2011) 1.24
Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens (2007) 1.23
Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol (2009) 1.22
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest (2012) 1.18
Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res (2003) 1.18
Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol (2004) 1.18
Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician (2011) 1.17
Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol (2011) 1.17
COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci (2003) 1.16
Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail (2009) 1.16
Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes (2003) 1.15
Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One (2010) 1.13
Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton) (2011) 1.12
Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant (2002) 1.11
High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. Am J Pathol (2007) 1.10
Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J (2003) 1.10
PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. J Am Soc Nephrol (2009) 1.07
Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res (2005) 1.04
Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol (2010) 1.03
Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells. Am J Physiol Renal Physiol (2006) 1.02
Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int (2004) 1.02
TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am J Physiol Renal Physiol (2005) 1.01
Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol (2005) 1.00
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol (2003) 0.99
Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. Nephrol Dial Transplant (2002) 0.96
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol (2011) 0.96
Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol (2004) 0.95
High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int (2005) 0.95
Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol (2007) 0.95
Fluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculature. PLoS One (2011) 0.94
Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes (2012) 0.94
The endothelium in diabetic nephropathy. Semin Nephrol (2012) 0.93
Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis (2004) 0.91
Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 0.89
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care (2002) 0.89
Hypertension revisited. Can Fam Physician (2012) 0.88
Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis. Stem Cells (2013) 0.88
High glucose induces macrophage inflammatory protein-3 alpha in renal proximal tubule cells via a transforming growth factor-beta 1 dependent mechanism. Nephrol Dial Transplant (2007) 0.87
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int (2002) 0.86
DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther (2013) 0.86
A study of VEGF and its receptors in two rat models of proteinuria. Nephron Physiol (2004) 0.86
Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care (2006) 0.86
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) (2014) 0.86
FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur J Heart Fail (2012) 0.86
STI-571 inhibits in vitro angiogenesis. Biochem Biophys Res Commun (2003) 0.86
SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci (2006) 0.86
Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade. Nephrology (Carlton) (2004) 0.85
Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol (2005) 0.85
Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant (2004) 0.84
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia (2014) 0.84
Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrol Dial Transplant (2003) 0.84
Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett (2009) 0.84
The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1. Nephrology (Carlton) (2007) 0.84
The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. J Hypertens (2011) 0.83
Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes. Diab Vasc Dis Res (2005) 0.83
Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol (2003) 0.83
Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant (2003) 0.83
Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension (2004) 0.83
Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol (2011) 0.82
Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation. Stem Cells Transl Med (2012) 0.82
Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia. Nephron Physiol (2007) 0.82
Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrol Dial Transplant (2009) 0.81
Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? Nephrol Dial Transplant (2003) 0.80
Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney Int (2002) 0.80
A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. Int J Cardiol (2012) 0.80
Prevention of cardiovascular disease: an evidence-based clinical aid 2004. Med J Aust (2004) 0.79
Chronic kidney disease in diabetes. Can J Diabetes (2013) 0.79
Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. CMAJ (2013) 0.79
Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. Clin Invest Med (2014) 0.78
Bone marrow cell therapies for endothelial repair and their relevance to kidney disease. Semin Nephrol (2012) 0.78
Expression of filtrin in human glomerular diseases. Nephrol Dial Transplant (2007) 0.78
3',4'-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy. Bioorg Med Chem Lett (2013) 0.77
Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction. Int J Cardiol (2009) 0.77
Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren-2 rats. Nephrology (Carlton) (2008) 0.76
Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies. Acta Diabetol (2014) 0.76
Letter by Connelly et al regarding article, "Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension". Circulation (2008) 0.75
Hyperglycemia and renal mass ablation synergistically augment albuminuria in the diabetic subtotally nephrectomized rat: implications for modeling diabetic nephropathy. Nephron Extra (2012) 0.75
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. Biomed Res Int (2013) 0.75
Novel risk factors for heart failure when the whole may be greater than the sum of its parts. J Am Coll Cardiol (2009) 0.75
Tranilast ameliorates experimental mesangial proliferative glomerulonephritis. Nephron Exp Nephrol (2008) 0.75
Progressive diabetic nephropathy in the Ren-2 rat. Am J Physiol Renal Physiol (2007) 0.75
Renin inhibition: new potential for an old therapeutic target. Hypertension (2005) 0.75
Treatment of hypertension. Can J Diabetes (2013) 0.75
Protein kinase C β inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Nephrology (Carlton) (2011) 0.75